Category: Patient Education

ASCO 2015 – WCMC Related Abstracts

In two weeks the 2015 meeting of the American Society of Clinical Oncology (ASCO) will take place in Chicago, bringing oncology professionals together from around the world. Below are the abstracts Lymphoma Program team members were involved in whole or in part to be presented at ASCO 2015:

CLL
Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation

Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).

Follicular Lymphoma
A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma

Non-Hodgkin Lymphoma
AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab 

Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE 

Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials

A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma 

Waldenstrom’s Macroglobulinemia
Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM)

Please look to this space for further updates about developments in ASCO 2015.

REDLAMP 4: Circulating Tumor DNA & CT Monitoring for Untreated DLBCL – A Correlative Biomarker Study

First-line chemotherapy for diffuse large B-cell lymphoma is given with curative intent, but is not always effective. In this video, Dr. Peter Martin discusses the implications of a recently published study in Lancet Oncology, which aimed to discover whether a blood test capable of detecting circulating tumor DNA might predict treatment success or failure. In the future, blood tests may be added to, or even replace, current standard surveillance methods like CT scans or PET scans.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

Ask the Doctor: Updates on Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma

The Lymphoma Research Foundation’s (LRF) “Ask the Doctor About Lymphoma” programs are designed specifically for people affected by lymphoma. Tonight’s two-hour topic-specific seminar will feature a presentation led by Director of the CLL Research Center, Dr. Richard Furman. The presentation will be followed by a Q&A session. Online registration is available here. Program details are below:

Ask the Doctor: Updates on Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma

Richard R. Furman, MD
Associate Professor of Medicine
Director of the CLL Research Center
Weill Cornell Medical College
New York, NY
Follow Dr. Furman on Twitter

Date and Time
Tuesday, May 12, 2015
Networking: 6:00 PM
Program: 6:30 PM – 8:30 PM

Location
New York Marriott East Side
525 Lexington Ave at 49th Street
New York, NY 10017
www.marriott.com

Meals
Dinner will be provided for all registered attendees.

Program Overview – Online registration here

  • Overview and Treatment Options on CLL/SLL
  • Understanding Clinical Trials and Novel Therapies for CLL/SLL
  • Question and Answer Session

Registration Instructions
This program is offered free-of-charge to members of the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma community however, pre-registration is required. Please note: The names and phone numbers and/or email address for all attendees is required to complete the registration.

Three Easy Ways to Register!

Call: 800-500-9976
Email: mspellman@lymphoma.org
Web: Click here